Provided by Tiger Fintech (Singapore) Pte. Ltd.

Leap Therapeutics Inc

0.4334
-0.0020-0.46%
Volume:230.85K
Turnover:99.78K
Market Cap:16.61M
PE:-0.23
High:0.4435
Open:0.4327
Low:0.4244
Close:0.4354
Loading ...

Company Profile

Company Name:
Leap Therapeutics Inc
Exchange:
NASDAQ
Establishment Date:
2011
Employees:
54
Office Location:
47 Thorndike Street,Suite B1-1,Cambridge,Massachusetts,United States
Zip Code:
02141
Fax:
- -
Introduction:
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase I clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.

Directors

Name
Position
Christopher K. Mirabelli
Chairman, Chief Executive Officer and President
James Cavanaugh
Director
John Littlechild
Director
Joseph Loscalzo
Director
Nissim Mashiach
Director
Thomas Dietz
Director
William Li
Director

Shareholders

Name
Position
Christopher K. Mirabelli
Chairman, Chief Executive Officer and President
Augustine J. Lawlor
Chief Operating Officer
Douglas E. Onsi
Chief Financial Officer, General Counsel, Treasurer and Secretary